Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 3/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HPD | P32754 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31161039 | 0.84 | SMN1; SMN2 (0.36) | S1PR2KDM4EHSD17B10HTTALDH1A1 | |
| SCHEMBL320650 | 0.75 | HTT (0.38) | KDM4EHTTALDH1A1MAPT | |
| SCHEMBL31160996 | 0.74 | HDAC1 (0.38) | S1PR2KDM4EHSD17B10ALDH1A1MAPT | |
| SCHEMBL14917190 | 0.74 | NPC1 (0.40) | KDM4EHSD17B10HTTALDH1A1MAPT | |
| SCHEMBL14916426 | 0.74 | MAPT (0.39) | KDM4EHSD17B10HTTALDH1A1TSHR | |
| SCHEMBL14916577 | 0.74 | BRD4 (0.40) | KDM4EHTTALDH1A1MAPT | |
| SCHEMBL321051 | 0.72 | ALDH1A1 (0.44) | KDM4EALDH1A1MAPT | |
| SCHEMBL10086153 | 0.72 | PARG (0.59) | PARGGRIN1GRIN2B | |
| SCHEMBL320775 | 0.71 | POLB (0.41) | KDM4EHSD17B10HTTALDH1A1TSHR | |
| SCHEMBL14916473 | 0.71 | CDYL2 (0.38) | KDM4EHSD17B10HTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4688756-A1 | QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024206345-A1 | QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| US-8859544-B2 | Indolizine derivatives, process for the preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| US-20130116249-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, MYLK2 | PARG 2555/4885S1PR2 4599/4885TNF 4710/4885 |
| US-20130116249-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, INMT, IDO1 | PARG 1457/4885S1PR2 2252/4885TNF 1952/4885 |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | TNNI3, TNNT2, TNNC1 | PARG 4462/4885S1PR2 3348/4885TNF 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.